Cargando…

P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY

Detalles Bibliográficos
Autores principales:	Spurgeon, Stephen, Mei, Matthew, Barr, Paul M., Barrientos, Jacqueline, de Vos, Sven, Furman, Richard, Patel, Krish, Thompson, Philip, Choi, Michael Y., Kallam, Avyakta, Wang, Siruo, Ogbu, Uzor, Marinello, Patricia, Wang, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430916/ http://dx.doi.org/10.1097/01.HS9.0000971696.54506.b2

Ejemplares similares

P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE
por: Wang, M., et al.
Publicado: (2022)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Ozcan, Muhit, et al.
Publicado: (2023)

Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability
por: Zain, Jasmine, et al.
Publicado: (2023)

PB2140: ALLOGENEIC STEM CELL TRANSPLANTATION IN RARE T-NHL SUBTYPES: FOCUS ON AITL, MF/SS, HSTCL. A SINGLE BMT-UNIT EXPERIENCE.
por: Tzenou, T., et al.
Publicado: (2022)

COLLABORATION FRAMEWORK AGREEMENT KN 2140 DG
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2013)

Undifferentiated Embryonal Sarcoma of Liver
por: Kallam, Avyakta, et al.
Publicado: (2015)

The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells
por: Liu, Dongli, et al.
Publicado: (2022)

ADDENDUM No.1TO COLLABORATION AGREEMENT KN2140/DG
por: The European Organization for Nuclear Research, CERN, et al.
Publicado: (2014)

2140: Estimating microscopic structures of glomeruli in renal pathology
por: Sarder, Pinaki, et al.
Publicado: (2018)

Antiproton Stacking, Run 1200, 29.5.81, R2
por: Ciapala, Edmond
Publicado: (1981)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
por: Muir, Kate-Lynn, et al.
Publicado: (2021)

Biomarkers in NHL
por: Malek, Sami N.
Publicado: (2011)

P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB-BASED ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
por: Meinke, S., et al.
Publicado: (2022)

Run 36, 15 GeV, 21.05-21.40
por: Keil, Eberhard
Publicado: (1971)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy
por: Burke, G. A. Amos, et al.
Publicado: (2020)

Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2020)

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
por: Harker-Murray, Paul, et al.
Publicado: (2023)

World Health Organization
por: Ogbu, Uzor C., et al.
Publicado: (2017)

Upper Limb Phlegmasia Cerulea Dolens Secondary to Heparin-induced Thrombocytopenia Leading to Gangrene
por: Kommalapati, Anuhya, et al.
Publicado: (2018)

Stem cell hunt in NHL
por: Merkel, Olaf, et al.
Publicado: (2015)

NHL - Extranodal T-cell lymphoma
por: Devi, Seema, et al.
Publicado: (2015)

Polysubstance Abuse: Alcohol, Opioids and Benzodiazepines Require Coordinated Engagement by Society, Patients, and Physicians
por: Ogbu, Uzor C., et al.
Publicado: (2015)

Exploring Potential Germline-Associated Roles of the TRIM-NHL Protein NHL-2 Through RNAi Screening
por: Davis, Gregory M., et al.
Publicado: (2017)

TRIM-NHL protein, NHL-2, modulates cell fate choices in the C. elegans germ line
por: Brenner, John L., et al.
Publicado: (2022)

Comparative structural analyses of the NHL domains from the human E3 ligase TRIM–NHL family
por: Chaikuad, Apirat, et al.
Publicado: (2022)

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
por: Aubrais, Raphaelle, et al.
Publicado: (2022)

Brentuximab Vedotin
Publicado: (2012)

Non-Hodgkin Lymphoma (NHL) in Pakistan
por: Pervez, Shahid
Publicado: (2012)

The TRIM-NHL protein NHL-2 is a co-factor in the nuclear and somatic RNAi pathways in C. elegans
por: Davis, Gregory M, et al.
Publicado: (2018)

LncRNA RGMB-AS1 Promotes Glioma Growth and Invasion Through miR-1200/HOXB2 Axis
por: Pan, Bailin, et al.
Publicado: (2019)

Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations
por: Hoa, S., et al.
Publicado: (2016)

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Artes pictóricas en occidente, 800-1200
por: Dodwell, Charles Reginald
Publicado: (1995)

Arquitectura carolingia y románica, 800-1200
por: Conant, Kenneth John, 1894-1984
Publicado: (1995)

A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy
por: Mallipudi, Rajiv M., et al.
Publicado: (2019)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

2140. Healthcare-Associated Infection Outbreak Investigation of an Elevation of Surgical Site Infections at a Critical Access Hospital
por: Pedati, Caitlin, et al.
Publicado: (2018)

2140. Utility of Respiratory Specimen Gram Stain for Predicting Final Culture Result in Patients with Clinically Diagnosed Pneumonia
por: Seadler, Jessica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iqj5qps3i2vbqs53hmnjno80qu